189 related articles for article (PubMed ID: 36848235)
1. Protein adduction causes non-mutational inhibition of p53 tumor suppressor.
Caspa Gokulan R; Paulrasu K; Azfar J; El-Rifai W; Que J; Boutaud OG; Ban Y; Gao Z; Buitrago MG; Dikalov SI; Zaika AI
Cell Rep; 2023 Jan; 42(1):112024. PubMed ID: 36848235
[TBL] [Abstract][Full Text] [Related]
2. Isolevuglandins (isoLGs) as toxic lipid peroxidation byproducts and their pathogenetic role in human diseases.
Aschner M; Nguyen TT; Sinitskii AI; Santamaría A; Bornhorst J; Ajsuvakova OP; da Rocha JBT; Skalny AV; Tinkov AA
Free Radic Biol Med; 2021 Jan; 162():266-273. PubMed ID: 33099003
[TBL] [Abstract][Full Text] [Related]
3. p73 is transcriptionally regulated by DNA damage, p53, and p73.
Chen X; Zheng Y; Zhu J; Jiang J; Wang J
Oncogene; 2001 Feb; 20(6):769-74. PubMed ID: 11314010
[TBL] [Abstract][Full Text] [Related]
4. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.
Grönroos E; Terentiev AA; Punga T; Ericsson J
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12165-70. PubMed ID: 15295102
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of p73 and p53 regulation and effector functions.
Fang L; Lee SW; Aaronson SA
J Cell Biol; 1999 Nov; 147(4):823-30. PubMed ID: 10562283
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
7. Effect of hydroxyurea on the promoter occupancy profiles of tumor suppressor p53 and p73.
Huang V; Lu X; Jiang Y; Wang JY
BMC Biol; 2009 Jun; 7():35. PubMed ID: 19558638
[TBL] [Abstract][Full Text] [Related]
8. p73, a gene related to p53, is not mutated in esophageal carcinomas.
Nimura Y; Mihara M; Ichimiya S; Sakiyama S; Seki N; Ohira M; Nomura N; Fujimori M; Adachi W; Amano J; He M; Ping YM; Nakagawara A
Int J Cancer; 1998 Nov; 78(4):437-40. PubMed ID: 9797131
[TBL] [Abstract][Full Text] [Related]
9. p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner.
Zhu J; Nozell S; Wang J; Jiang J; Zhou W; Chen X
Oncogene; 2001 Jul; 20(30):4050-7. PubMed ID: 11494133
[TBL] [Abstract][Full Text] [Related]
10. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.
Byun DS; Chae KS; Ryu BK; Lee MG; Chi SG
Int J Cancer; 2002 Apr; 98(5):718-23. PubMed ID: 11920641
[TBL] [Abstract][Full Text] [Related]
11. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
12. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints.
Wang S; El-Deiry WS
Cancer Res; 2006 Jul; 66(14):6982-9. PubMed ID: 16849542
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of p73 and p53 in human cancer cell lines.
Yoshikawa H; Nagashima M; Khan MA; McMenamin MG; Hagiwara K; Harris CC
Oncogene; 1999 Jun; 18(22):3415-21. PubMed ID: 10362363
[TBL] [Abstract][Full Text] [Related]
14. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
15. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.
Gorgoulis VG; Vassiliou LV; Karakaidos P; Zacharatos P; Kotsinas A; Liloglou T; Venere M; Ditullio RA; Kastrinakis NG; Levy B; Kletsas D; Yoneta A; Herlyn M; Kittas C; Halazonetis TD
Nature; 2005 Apr; 434(7035):907-13. PubMed ID: 15829965
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
17. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Nicholson SA; Okby NT; Khan MA; Welsh JA; McMenamin MG; Travis WD; Jett JR; Tazelaar HD; Trastek V; Pairolero PC; Corn PG; Herman JG; Liotta LA; Caporaso NE; Harris CC
Cancer Res; 2001 Jul; 61(14):5636-43. PubMed ID: 11454718
[TBL] [Abstract][Full Text] [Related]
18. Differential modulation of cellular and viral promoters by p73 and p53.
Deb D; Lanyi A; Scian M; Keiger J; Brown DR; Le Roith D; Deb SP; Deb S
Int J Oncol; 2001 Feb; 18(2):401-9. PubMed ID: 11172610
[TBL] [Abstract][Full Text] [Related]
19. p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis.
Ito S; Ohga T; Saeki H; Nakamura T; Watanabe M; Tanaka S; Kakeji Y; Maehara Y
Int J Cancer; 2005 Jan; 113(1):22-8. PubMed ID: 15386362
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
